2018
Lymphatics in the liver
Tanaka M, Iwakiri Y. Lymphatics in the liver. Current Opinion In Immunology 2018, 53: 137-142. PMID: 29772409, PMCID: PMC6986420, DOI: 10.1016/j.coi.2018.04.028.BooksMeSH KeywordsAnimalsCarcinoma, HepatocellularEndothelial CellsHepatitis, Viral, HumanHumansLiverLiver CirrhosisLymphangiogenesisLymphatic VesselsConceptsHepatic lymphatic systemLymphatic systemViral hepatitisLiver diseaseLarge lymphHepatic lymphatic vesselsDiseased liverHepatocellular carcinomaLymphatic endothelial cellsEndothelial cellsLiverLymphatic vesselsPotential roleSignificant increaseDiseaseCurrent knowledgeReview articleOrgansCirrhosisHepatitisLymphCarcinomaLymphatics
2017
The portal hypertension syndrome: etiology, classification, relevance, and animal models
Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International 2017, 12: 1-10. PMID: 29064029, DOI: 10.1007/s12072-017-9827-9.BooksMeSH KeywordsAdrenergic beta-AntagonistsAnimalsAscitesCarcinoma, HepatocellularEarly Detection of CancerEsophageal and Gastric VaricesGastrointestinal HemorrhageHealthy LifestyleHemorrhageHepatic EncephalopathyHepatic VeinsHumansHypertension, PortalHypolipidemic AgentsLigationLiver CirrhosisLiver NeoplasmsModels, AnimalPrognosisSimvastatinConceptsHepatic vein pressure gradientNon-bleeding complicationsPortal hypertensionLiver transplantationDisease stagePortal hypertension syndromeAccurate risk stratificationDevelopment of varicesEndoscopic band ligationAim of treatmentPresent day therapyHealthy life styleBackgroundPortal hypertensionDecompensated patientsHVPG responseRefractory ascitesVariceal bleedingClinical decompensationLarge varicesBand ligationDay therapyHepatic encephalopathyBetter prognosisRisk stratificationEtiologic treatment
2003
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice
Gratton J, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng Y, Sessa WC. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003, 4: 31-39. PMID: 12892711, DOI: 10.1016/s1535-6108(03)00168-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCapillary PermeabilityCarcinoma, HepatocellularCarcinoma, Lewis LungCaveolin 1CaveolinsDisease ProgressionEndothelium, VascularEnzyme InhibitorsLiver Neoplasms, ExperimentalLung NeoplasmsMaleMiceMice, Inbred C57BLMice, KnockoutMice, NudeNeovascularization, PhysiologicNitric Oxide SynthaseNitric Oxide Synthase Type IINitric Oxide Synthase Type IIIPeptide FragmentsVascular Endothelial Growth Factor AConceptsEndothelial nitric oxide synthaseTumor progressionAntitumor actionDelays tumor progressionENOS knockout miceNitric oxide synthaseTumor blood vesselsTumor microvascular permeabilityOxide synthaseMicrovascular permeabilityKnockout miceAntiangiogenic effectsTumor vasculatureCell-permeable peptideMicrovascular hyperpermeabilityNovel targetNormal vasculatureHyperpermeabilityBlood vesselsCavtratinAntitumor therapyProgressionMiceSelective inhibitionVasculature